GuideHaematology
2-year PFS2 with second-line BTK inhibitors in mantle cell lymphoma (2L BTKi MIPI)
Reading sheet on the Villa et al. nomogram and prognostic index for relapsed mantle cell lymphoma starting a BTK inhibitor as second-line therapy.
Updated 3 November 2026
When to use it
Relapsed or refractory mantle cell lymphoma after rituximab-based first-line therapy, when a second-line BTK inhibitor is planned and the expected duration of control is needed to plan CAR-T, allogeneic transplant or other therapies.
What it is and for whom
International multicentre model (8 centres; 160 patients in the main cohort and 200 in the validation cohort) in relapsed or refractory mantle cell lymphoma starting single-agent BTK inhibitor as second-line therapy after rituximab-based first-line treatment. It estimates progression-free survival from the start of second-line therapy (PFS2) and overall survival (OS2).
Keep reading in the app
- Model variables
- Published interpretation
- Practical use
- Limitations
Practical tip
Time to progression after first-line therapy carries the most weight: refractory disease or progression within 6 months (POD6) predicts very short control on the BTK inhibitor.
2 more practical tips in the app.
Reference
A support tool for healthcare professionals: it guides and does not replace clinical judgement.
